Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 25, 2009

Daiichi Sankyo Obtains Rights to Gene Bridges’ Recombineering Technology

  • Daiichi Sankyo has inked a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology is a method for generating targeting vectors or modifying E. coli chromosomes.
     
    According to Gene Bridges, recombineering with Red/ET allows cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including large ones such as BACs or the E.coli chromosome.

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »